Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Hikma Pharmaceuticals

Hikma Pharmaceuticals
1978 FOUNDED
PUBLIC STATUS
5K-10K EMPLOYEES
HIK STOCK SYMBOL
19 INVESTMENTS
$24.58 SHARE PRICE (As of Wednesday Closing)
Description

Founded in the Middle East and with headquarters in London, Hikma manufactures generic and in-licensed pharmaceuticals. The firm operates in three segments: injectables, generics, branded, and other, which comprise most of the company's revenue at about 40%, 33%, and 26%, respectively. About 63%, 32%, and 6% of Hikma's sales are based in the U.S., Middle East, North Africa, and Europe, and Other.

Website
Ownership Status
Publicly Held
Financing Status
Corporation
Primary Industry
Pharmaceuticals
Other Industries
Drug Discovery
Stock Exchange
LON
Primary Office
  • 1 New Burlington Place
  • London W1S 2HR
  • England, United Kingdom

+44 020 0000 0000
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Hikma Pharmaceuticals’s full profile, request a free trial.

Hikma Pharmaceuticals Stock Performance

52 wk Range Market Cap Prev. Close EPS Average Volume Shares
$19.63 - $27.26 $5.96B $24.67 $1.49 609K 242M

Hikma Pharmaceuticals Financials Summary

In Thousands,
USD
TTM
30-Jun-2019
FY 2018
31-Dec-2018
FY 2017
31-Dec-2017
FY 2016
31-Dec-2016
Enterprise Value 5,638,341 5,750,556 4,294,666 6,399,338
Revenue 2,138,000 2,070,000 1,936,000 1,950,000
EBITDA 505,000 440,000 (553,000) 368,000
Net Income 361,000 282,000 (843,000) 155,000
Total Assets 3,606,000 3,497,000 3,388,000 4,363,000
Total Debt 695,000 637,000 777,000 860,000
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Hikma Pharmaceuticals Valuation and Funding

Deal Type Date Amount Post-Val Valuation/
EBITDA
Debt Status

This information is reserved for PitchBook Platform users. To explore Hikma Pharmaceuticals‘s full profile, request access.

Request full access to PitchBook

Hikma Pharmaceuticals Competitors (4)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Mylan Corporation Hatfield, United Kingdom 00000 00.00 000000&0 00.00
000000 00000000000 Corporation Tokyo, Japan 00000 0000
000 00000000000000 Corporation Mumbai, India 00000 00000000000
000000 Corporation Carros, France 0000
To view this company’s complete list of competitors, request access »

Hikma Pharmaceuticals Investments & Acquisitions (19)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
000000 000000 (000 08-Nov-2018 000000000000000000 Medical Supplies 0000 000000000
000000 00000000000 29-Feb-2016 000000000000000000 00.000 Pharmaceuticals 0000 00000000
0000 000000 000000 17-Feb-2016 000000000000000000 000.00 Drug Discovery
000000000000000 00 17-Sep-2014 000000000 00000 00 Buildings and Property 0000 00000000
Bedford Laboratories 15-Jul-2014 Merger/Acquisition 00000 Medical Supplies 0000 00000000
To view this company’s complete investment and acquisition history, request access »

Hikma Pharmaceuticals Exits (3)

Company Name Exit Date Exit Type Exit Size Status Buyers
000000000000000 00 17-Sep-2014 000000000 00000 00 Completed
  • 00000 000000000000
000 00000 00000000 15-Jul-2014 000000000000000000 00000 Completed
  • 00000 000000000000
Unimark Remedies 16-May-2011 Corporate 000.00 Completed
To view this company’s complete exits history, request access »

Hikma Pharmaceuticals Subsidiaries (5)

Company Name Industry Location Founded
Hikma Ventures Corporate Venture Capital London, United Kingdom 2015
0000 000000 000000 Drug Discovery Cairo, Egypt 0000
00000000000 Distributors (Healthcare) Gräfelfing, Germany 0000
0000 0000000000000 Acquirer Al Salt, Jordan 0000
0000000000 Pharmaceuticals Casablanca, Morocco 0000
To view this company’s complete subsidiary history, request access »

Hikma Pharmaceuticals Executive Team (25)

Name Title Board
Seat
Contact
Info
Sigurdur Olafsson Chief Executive Officer & Board Member
Riad Mechlaoui President of Injectables
Khalid Nabilsi Chief Financial Officer
Bassam Kanaan Chief Strategy and Corporate Development Officer
Surendera Tyagi Ph.D Chief Scientific Officer & Global Head, Research & Development

5 Former Executives

You’re viewing 5 of 25 executives. Get the full list »

Hikma Pharmaceuticals Board Members (11)

Name Representing Role Since Contact
Info
000 00-00000 Self Board Member 000 0000
000000 0000 Self Board Member 000 0000
0000 0000000000 Hikma Pharmaceuticals Board Member 000 0000
00000 00000 00000 00000000 Hikma Pharmaceuticals Executive Vice Chairman, President and Chief Executive of MENA and Emerging Markets 000 0000
0000 000000000 Self Board Member 000 0000

1 Former Board Member

You’re viewing 5 of 11 board members. Get the full list »